These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 8039940)

  • 41. Plasma levels of main granulocyte components during cardiopulmonary bypass.
    Riegel W; Spillner G; Schlosser V; Hörl WH
    J Thorac Cardiovasc Surg; 1988 Jun; 95(6):1014-9. PubMed ID: 2836662
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Deleterious effects of cardiopulmonary bypass. A prospective study of bubble versus membrane oxygenation.
    van Oeveren W; Kazatchkine MD; Descamps-Latscha B; Maillet F; Fischer E; Carpentier A; Wildevuur CR
    J Thorac Cardiovasc Surg; 1985 Jun; 89(6):888-99. PubMed ID: 3158783
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of complement inhibition and heparin coating on artificial surface-induced leukocyte and platelet activation.
    Lappegård KT; Fung M; Bergseth G; Riesenfeld J; Lambris JD; Videm V; Mollnes TE
    Ann Thorac Surg; 2004 Mar; 77(3):932-41. PubMed ID: 14992902
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical performance of a high-efficiency rapid flow leucocyte removal filter for leucocyte depletion of heparinized cardiopulmonary bypass perfusate.
    Gu YJ; deVries AJ; Boonstra PW; van Oeveren W
    Perfusion; 1995 Nov; 10(6):425-30. PubMed ID: 8747899
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Blood-air interface during cardiopulmonary bypass.
    Kiessling AH; Khalil M; Assaf O; Isgro F; Kretz KU; Saggau W
    Asian Cardiovasc Thorac Ann; 2004 Sep; 12(3):198-201. PubMed ID: 15353455
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Comparison of biocompatibility of hemophane, cellulose diacetate and acrilonitile membranes in hemodialysis].
    Germin Petrović D
    Acta Med Croatica; 2004; 58(1):31-6. PubMed ID: 15125391
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cardiopulmonary bypass parameters and hemostatic response to cardiopulmonary bypass in infants versus children.
    Eisses MJ; Chandler WL
    J Cardiothorac Vasc Anesth; 2008 Feb; 22(1):53-9. PubMed ID: 18249331
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Characterization of the anaphylatoxin inactivator and chemotactic factor inactivator activities during cardiopulmonary bypass.
    Kreutzer DL; McCormick JR; Despins A; Moore M; Rousou JH; Dobbs W; Engleman RN
    J Exp Pathol; 1984; 1(3):183-7. PubMed ID: 6336305
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of cardiopulmonary bypass on systemic release of neutrophil elastase and tumor necrosis factor.
    Butler J; Parker D; Pillai R; Westaby S; Shale DJ; Rocker GM
    J Thorac Cardiovasc Surg; 1993 Jan; 105(1):25-30. PubMed ID: 8419705
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of a Duraflo II-coated cardiopulmonary bypass circuit and a trillium-coated oxygenator during open-heart surgery.
    Hoel TN; Videm V; Baksaas ST; Mollnes TE; Brosstad F; Svennevig JL
    Perfusion; 2004 May; 19(3):177-84. PubMed ID: 15298426
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [A clinical study of respiratory complication after cardiopulmonary bypass, with special reference to complement activation, WBC and granulocyte elastase].
    Nagamine S; Tabayashi K; Haneda K; Mohri H
    Nihon Geka Gakkai Zasshi; 1994 May; 95(5):348-53. PubMed ID: 8007941
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Biocompatibility of hemodialysis membranes: interrelations between plasma complement and cytokine levels.
    Varela MP; Kimmel PL; Phillips TM; Mishkin GJ; Lew SQ; Bosch JP
    Blood Purif; 2001; 19(4):370-9. PubMed ID: 11574733
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Contact, coagulation and platelet interaction with heparin treated equipment during heart surgery.
    van der Kamp KW; van Oeveren W
    Int J Artif Organs; 1993 Dec; 16(12):836-42. PubMed ID: 8175200
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [In vitro and clinical study of complement activation during cardiopulmonary bypass with reference to types of oxygenator, primed autologous blood and patient's factor].
    Oda K
    Nihon Kyobu Geka Gakkai Zasshi; 1991 Sep; 39(9):1703-11. PubMed ID: 1960449
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An alternative pathway for fibrinolysis is activated in patients who have undergone cardiopulmonary bypass surgery and major abdominal surgery.
    Gando S; Kameue T; Sawamura A; Hayakawa M; Hoshino H; Kubota N
    Thromb Res; 2007; 120(1):87-93. PubMed ID: 17023030
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clivarin and other LMWHs in an ex vivo cardiopulmonary bypass model. Studies on contact activation.
    Heller W; Wendel HP
    Blood Coagul Fibrinolysis; 1993 Dec; 4 Suppl 1():S45-54. PubMed ID: 8180329
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Strategies to reduce hemostatic activation during cardiopulmonary bypass.
    Eisses MJ; Velan T; Aldea GS; Chandler WL
    Thromb Res; 2006; 117(6):689-703. PubMed ID: 15996721
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Monitoring of the blood response in blood purification.
    Courtney JM; Sundaram S; Lamba NM; Forbes CD
    Artif Organs; 1993 Apr; 17(4):260-6. PubMed ID: 8498906
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Significance of the concentrated red cell and albumin priming method with particular reference to anaphylatoxin generation.
    Tamiya T; Maeo Y; Okada T; Ogoshi S; Fujimoto S; Yasui H
    J Thorac Cardiovasc Surg; 1992 Jan; 103(1):78-86. PubMed ID: 1728718
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of methylprednisolone and a biocompatible copolymer circuit on blood activation during cardiopulmonary bypass.
    Rubens FD; Nathan H; Labow R; Williams KS; Wozny D; Karsh J; Ruel M; Mesana T
    Ann Thorac Surg; 2005 Feb; 79(2):655-65. PubMed ID: 15680854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.